• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

目标性肌萎缩侧索硬化症

Destination Amyotrophic Lateral Sclerosis.

作者信息

Keon Matt, Musrie Benjamin, Dinger Marcel, Brennan Samuel E, Santos Jerran, Saksena Nitin K

机构信息

GenieUs Genomics Pty Ltd., Sydney, NSW, Australia.

School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia.

出版信息

Front Neurol. 2021 Mar 29;12:596006. doi: 10.3389/fneur.2021.596006. eCollection 2021.

DOI:10.3389/fneur.2021.596006
PMID:33854469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8039771/
Abstract

Amyotrophic Lateral Sclerosis (ALS) is a prototypical neurodegenerative disease characterized by progressive degeneration of motor neurons both in the brain and spinal cord. The constantly evolving nature of ALS represents a fundamental dimension of individual differences that underlie this disorder, yet it involves multiple levels of functional entities that alternate in different directions and finally converge functionally to define ALS disease progression. ALS may start from a single entity and gradually becomes multifactorial. However, the functional convergence of these diverse entities in eventually defining ALS progression is poorly understood. Various hypotheses have been proposed without any consensus between the for-and-against schools of thought. The present review aims to capture explanatory hierarchy both in terms of hypotheses and mechanisms to provide better insights on how they functionally connect. We can then integrate them within a common functional frame of reference for a better understanding of ALS and defining future treatments and possible therapeutic strategies. Here, we provide a philosophical understanding of how early leads are crucial to understanding the endpoints in ALS, because invariably, all early symptomatic leads are underpinned by neurodegeneration at the cellular, molecular and genomic levels. Consolidation of these ideas could be applied to other neurodegenerative diseases (NDs) and guide further critical thinking to unveil their roadmap of destination ALS.

摘要

肌萎缩侧索硬化症(ALS)是一种典型的神经退行性疾病,其特征是大脑和脊髓中的运动神经元进行性退化。ALS不断演变的特性代表了构成这种疾病基础的个体差异的一个基本维度,但它涉及多个功能实体层面,这些层面在不同方向上交替变化,最终在功能上汇聚以定义ALS疾病的进展。ALS可能始于单一实体,然后逐渐变得多因素化。然而,这些不同实体在最终定义ALS进展过程中的功能汇聚却鲜为人知。已经提出了各种假设,但支持和反对的学派之间没有达成任何共识。本综述旨在从假设和机制方面捕捉解释层次,以便更好地洞察它们在功能上是如何联系的。然后,我们可以将它们整合到一个共同的功能参考框架内,以更好地理解ALS,并确定未来的治疗方法和可能的治疗策略。在这里,我们从哲学角度理解早期线索对于理解ALS终点的重要性,因为所有早期症状线索无一例外地都在细胞、分子和基因组水平上以神经退变为基础。这些观点的整合可应用于其他神经退行性疾病(NDs),并指导进一步的批判性思维,以揭示它们通向ALS的路线图。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/5d3d8a3605b5/fneur-12-596006-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/7dbbeee45a38/fneur-12-596006-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/91e5a42475f6/fneur-12-596006-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/ca819aa6e00f/fneur-12-596006-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/5d3d8a3605b5/fneur-12-596006-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/7dbbeee45a38/fneur-12-596006-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/91e5a42475f6/fneur-12-596006-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/ca819aa6e00f/fneur-12-596006-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c78/8039771/5d3d8a3605b5/fneur-12-596006-g0003.jpg

相似文献

1
Destination Amyotrophic Lateral Sclerosis.目标性肌萎缩侧索硬化症
Front Neurol. 2021 Mar 29;12:596006. doi: 10.3389/fneur.2021.596006. eCollection 2021.
2
The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis.代谢稳态与神经退行性变之间的相互作用:对肌萎缩侧索硬化症神经代谢本质的见解。
Cell Regen. 2015 Aug 27;4(1):5. doi: 10.1186/s13619-015-0019-6. eCollection 2015.
3
Macrophage-mediated inflammation and glial response in the skeletal muscle of a rat model of familial amyotrophic lateral sclerosis (ALS).家族性肌萎缩侧索硬化症(ALS)大鼠模型骨骼肌中巨噬细胞介导的炎症和神经胶质反应。
Exp Neurol. 2016 Mar;277:275-282. doi: 10.1016/j.expneurol.2016.01.008. Epub 2016 Jan 13.
4
Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis.肌萎缩侧索硬化症神经退行性变的临床治疗策略
Arch Ital Biol. 2011 Mar;149(1):151-67. doi: 10.4449/aib.v149i1.1267.
5
New insights into the gene expression associated to amyotrophic lateral sclerosis.肌萎缩侧索硬化症相关基因表达的新见解。
Life Sci. 2018 Jan 15;193:110-123. doi: 10.1016/j.lfs.2017.12.016. Epub 2017 Dec 11.
6
Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease.运动神经元病中颈上脊髓的横断和纵向评估。
Neuroimage Clin. 2019;24:101984. doi: 10.1016/j.nicl.2019.101984. Epub 2019 Aug 16.
7
RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue.RNS60 通过保护神经胶质细胞和周围神经来发挥治疗作用,对 SOD1 ALS 模型小鼠有效。
J Neuroinflammation. 2018 Mar 1;15(1):65. doi: 10.1186/s12974-018-1101-0.
8
Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.运动皮层中突变型 SOD1 的抑制可使 SOD1G93A 肌萎缩侧索硬化症大鼠模型的发病延迟和生存时间延长。
J Neurosci. 2014 Nov 19;34(47):15587-600. doi: 10.1523/JNEUROSCI.2037-14.2014.
9
Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.Ephrin-A5 的减少会加重肌萎缩侧索硬化症的疾病进展。
Acta Neuropathol Commun. 2019 Jul 12;7(1):114. doi: 10.1186/s40478-019-0759-6.
10
CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target?肌萎缩侧索硬化症中的中枢神经系统葡萄糖代谢:一个治疗靶点?
Cell Biosci. 2021 Jan 11;11(1):14. doi: 10.1186/s13578-020-00511-2.

引用本文的文献

1
Trimeric superoxide dismutase 1 antibody as a universal biomarker for ALS.三聚体超氧化物歧化酶1抗体作为肌萎缩侧索硬化症的通用生物标志物。
Res Sq. 2025 Jul 15:rs.3.rs-6941118. doi: 10.21203/rs.3.rs-6941118/v1.
2
Image-Guided Monitoring of Mitochondria and Blood-Brain Barrier Dysfunction in Amyotrophic Lateral Sclerosis Mice.肌萎缩侧索硬化症小鼠中线粒体和血脑屏障功能障碍的图像引导监测
Biomater Res. 2025 Mar 17;29:0162. doi: 10.34133/bmr.0162. eCollection 2025.
3
Circulating miR-223/NLRP3 axis and IL-1β level in functional disease progression of amyotrophic lateral sclerosis.

本文引用的文献

1
A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis.一项关于肌萎缩侧索硬化症微生物组组成的前瞻性纵向研究。
BMC Med. 2020 Jun 17;18(1):153. doi: 10.1186/s12916-020-01607-9.
2
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD.分歧、趋同与治疗意义:从细胞生物学角度看C9ORF72相关的肌萎缩侧索硬化症/额颞叶痴呆
Mol Neurodegener. 2020 Jun 8;15(1):34. doi: 10.1186/s13024-020-00383-7.
3
Connecting RNA-Modifying Similarities of TDP-43, FUS, and SOD1 with MicroRNA Dysregulation Amidst A Renewed Network Perspective of Amyotrophic Lateral Sclerosis Proteinopathy.
循环miR-223/NLRP3轴与白细胞介素-1β水平在肌萎缩侧索硬化症功能疾病进展中的作用
Acta Neurol Belg. 2025 Mar 18. doi: 10.1007/s13760-025-02764-5.
4
Complex Genetic Framework in Familial Amyotrophic Lateral Sclerosis With a C9ORF72 Mutation: A Case Report.伴有C9ORF72突变的家族性肌萎缩侧索硬化症的复杂遗传框架:病例报告
Cureus. 2024 Dec 19;16(12):e76027. doi: 10.7759/cureus.76027. eCollection 2024 Dec.
5
Targeting Protein Aggregation in ALS.靶向肌萎缩侧索硬化症中的蛋白质聚集。
Biomolecules. 2024 Oct 18;14(10):1324. doi: 10.3390/biom14101324.
6
A microRNA diagnostic biomarker for amyotrophic lateral sclerosis.一种用于肌萎缩侧索硬化症的微小RNA诊断生物标志物。
Brain Commun. 2024 Sep 13;6(5):fcae268. doi: 10.1093/braincomms/fcae268. eCollection 2024.
7
The Current Landscape of Hypotheses Describing the Contribution of CD4+ Heterogeneous Populations to ALS.描述CD4 +异质群体对肌萎缩侧索硬化症贡献的假说现状
Curr Issues Mol Biol. 2024 Jul 23;46(8):7846-7861. doi: 10.3390/cimb46080465.
8
Unraveling the complexity of human brain: Structure, function in healthy and disease states.解析人类大脑的复杂性:健康与疾病状态下的结构和功能。
Ageing Res Rev. 2024 Sep;100:102414. doi: 10.1016/j.arr.2024.102414. Epub 2024 Jul 15.
9
Sporadic Amyotrophic Lateral Sclerosis Skeletal Muscle Transcriptome Analysis: A Comprehensive Examination of Differentially Expressed Genes.散发性肌萎缩侧索硬化症骨骼肌转录组分析:差异表达基因的全面研究。
Biomolecules. 2024 Mar 20;14(3):377. doi: 10.3390/biom14030377.
10
14-3-3 proteins-a moonlight protein complex with therapeutic potential in neurological disorder: in-depth review with Alzheimer's disease.14-3-3蛋白——一种在神经疾病中具有治疗潜力的多功能蛋白复合物:对阿尔茨海默病的深入综述
Front Mol Biosci. 2024 Feb 5;11:1286536. doi: 10.3389/fmolb.2024.1286536. eCollection 2024.
连接 TDP-43、FUS 和 SOD1 的 RNA 修饰相似性与肌萎缩侧索硬化症蛋白病中重新审视的网络视角下的 microRNA 失调。
Int J Mol Sci. 2020 May 14;21(10):3464. doi: 10.3390/ijms21103464.
4
Proteome Homeostasis Dysfunction: A Unifying Principle in ALS Pathogenesis.蛋白质组平衡失调:ALS 发病机制的统一原理。
Trends Neurosci. 2020 May;43(5):274-284. doi: 10.1016/j.tins.2020.03.002. Epub 2020 Apr 14.
5
The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication.肠道微生物群产生的短链脂肪酸在肠-脑通讯中的作用
Front Endocrinol (Lausanne). 2020 Jan 31;11:25. doi: 10.3389/fendo.2020.00025. eCollection 2020.
6
Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment.神经胶质细胞——肌萎缩侧索硬化症治疗的战略靶点
J Clin Med. 2020 Jan 18;9(1):261. doi: 10.3390/jcm9010261.
7
Consideration of gravity as a possible etiological factor in amyotrophic lateral sclerosis.考虑重力可能是肌萎缩侧索硬化的一个病因因素。
Med Hypotheses. 2019 Nov;132:109369. doi: 10.1016/j.mehy.2019.109369. Epub 2019 Aug 17.
8
Pathomechanisms of Blood-Brain Barrier Disruption in ALS.肌萎缩侧索硬化症中血脑屏障破坏的发病机制
Neurosci J. 2019 Jul 10;2019:2537698. doi: 10.1155/2019/2537698. eCollection 2019.
9
Potential roles of gut microbiome and metabolites in modulating ALS in mice.肠道微生物组和代谢物在调节小鼠 ALS 中的潜在作用。
Nature. 2019 Aug;572(7770):474-480. doi: 10.1038/s41586-019-1443-5. Epub 2019 Jul 22.
10
Amyotrophic lateral sclerosis as a multi-step process: an Australia population study.肌萎缩侧索硬化症作为一个多步骤的过程:一项澳大利亚人群研究。
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):532-537. doi: 10.1080/21678421.2018.1556697. Epub 2019 Jul 8.